<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031715</url>
  </required_header>
  <id_info>
    <org_study_id>ID 0912/14122018</org_study_id>
    <nct_id>NCT05031715</nct_id>
  </id_info>
  <brief_title>Berberine and Altered Fasting Glucose</brief_title>
  <official_title>Effectiveness of the Assumption of a Berberine Phytosoma-based Supplement on the Hematic Values of Glucose in a Group of Patients With Altered Fasting Glucose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda di Servizi alla Persona di Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda di Servizi alla Persona di Pavia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to evaluate the effectiveness of a food supplement, berberine&#xD;
      phytosome, which contributes to the control of blood sugar and the improvement of insulin&#xD;
      resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2020</start_date>
  <completion_date type="Anticipated">October 25, 2021</completion_date>
  <primary_completion_date type="Actual">May 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes on insulin resistance</measure>
    <time_frame>Changes from baseline insulin resistance at 4 weeks and at 8 weeks</time_frame>
    <description>Homeostasis Model Assessment (pt), for evaluate insulin resistance if &gt; 2,4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes on carbohydrate profile</measure>
    <time_frame>Changes from baseline carbohydrate profile at 4 weeks and at 8 weeks</time_frame>
    <description>Fasting Glucose (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes on carbohydrate profile</measure>
    <time_frame>Changes from baseline carbohydrate profile at 4 weeks and at 8 weeks</time_frame>
    <description>Glycated hemoglobin (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometry</measure>
    <time_frame>Changes from baseline anthropometry at 4 weeks and at 8 weeks</time_frame>
    <description>Weight (Kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometry</measure>
    <time_frame>Changes from baseline anthropometry at 4 weeks and at 8 weeks</time_frame>
    <description>Body Mass Index (Kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on anthropometry</measure>
    <time_frame>Changes from baseline anthropometry at 4 weeks and at 8 weeks</time_frame>
    <description>Waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on body composition</measure>
    <time_frame>Changes from baseline body composition at 4 weeks and at 8 weeks</time_frame>
    <description>Fat mass (g), Fat Free Mass (g), Visceral Adipose Tissue (g)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on lipid profile</measure>
    <time_frame>Changes from baseline lipid profile at 4 weeks and at 8 weeks</time_frame>
    <description>Total Cholesterol (mg/dl), High density lipoprotein Cholesterol (mg/dl), Low density lipoprotein Cholesterol (mg/dl), Triglycerides (mg/dl), Apolipoprotein A (mg/dl), Apolipoprotein B (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on safety</measure>
    <time_frame>Changes from baseline safety at 4 weeks and at 8 weeks</time_frame>
    <description>Alanine aminotransferase (IU/l), Aspartate aminotransferase (IU/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on safety</measure>
    <time_frame>Changes from baseline safety at 4 weeks and at 8 weeks</time_frame>
    <description>Gamma Glutamyl Transferase (U/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on safety</measure>
    <time_frame>Changes from baseline safety at 4 weeks and at 8 weeks</time_frame>
    <description>Creatinine (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on safety</measure>
    <time_frame>Changes from baseline safety at 4 weeks and at 8 weeks</time_frame>
    <description>Glomerural Filtrate Rate (ml/min)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Dietary supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Berberine Phytosome</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Berberine Phytosome</intervention_name>
    <description>2 tablets of 550 mg per day (1 before lunch and 1 before dinner)</description>
    <arm_group_label>Dietary supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fasting blood glucose range:100-125 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariangela Rondanelli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Casemiro Mondino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariangela Rondanelli</last_name>
    <phone>+390382381749</phone>
    <email>mariangela.rondanelli@unipv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mariangela Rondanelli</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariangela Rondanelli</last_name>
      <phone>0382381749</phone>
      <email>mariangela.rondanelli@unipv.it</email>
    </contact>
    <contact_backup>
      <last_name>Mariangela Rondanelli</last_name>
      <email>mariangela.rondanelli@unipv.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

